Maternal diabetes is the most common cause of neonatal hyperglycemia, accounting for approximately 50% of cases.

The primary goal of treating neonatal hyperglycemia is to maintain blood sugar levels within a normal range, typically between 45 and 90 mg/dL.

Polyuria, or excessive urination, is a common sign of neonatal hyperglycemia, as the body attempts to excrete excess glucose through the urine.

Intravenous fluids are the first-line treatment for neonatal hyperglycemia, as they help to dilute the glucose in the blood and promote hydration.

Insulin therapy is typically initiated when blood sugar levels exceed 250 mg/dL in neonates.

The target blood sugar range for neonates receiving insulin therapy is typically between 60 and 90 mg/dL.

Neonatal hyperglycemia can lead to a number of complications, including hypoglycemia, seizures, neurological damage, and long-term health problems.

Blood sugar monitoring should be performed every 1-2 hours in neonates with hyperglycemia to ensure that blood sugar levels are within the target range.

All of the above are risk factors for the development of neonatal hyperglycemia.

Insulin therapy should be continued until blood sugar levels are within the target range and the underlying cause of the hyperglycemia has been addressed.

All of the above are potential adverse effects of insulin therapy in neonates.

Restricting carbohydrate intake is the recommended dietary modification for neonates with hyperglycemia.

All of the above are signs of hypoglycemia in neonates.

All of the above are recommended treatments for hypoglycemia in neonates.

All of the above are long-term complications of neonatal hyperglycemia.